Details of the Drug

General Information of Drug (ID: DMRLZA1)

• Drug Name: ZW25
• Synonyms: Zanidatamab

Indication

Disease Entry	ICD 11	Status	REF
Biliary tract cancer	2C17	Phase 2	[1]
Breast cancer	2C60-2C65	Phase 2	[2]
Oesophagogastric junction cancer	2B71.Z	Phase 2	[2]
Ovarian cancer	2C73	Phase 1	[3]

• Drug Type: Antibody
• Cross-matching ID:
  UNII: Z20OC92TDI
  DrugBank ID: DB15471
  TTD ID: D0AJ9V
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT04466891) A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04224272) A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)